You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapse/Refratory Peripheral T Cell Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • circulating tumoral DNA detection
  • Rouen, France
    Centre Henri Becquerel
Oct 13, 2023

Minimal Residual Disease in Peripheral T-cell Lymphoma

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 19, 2022

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Peripheral T Cell Lymphoma Trial in Shandong, Shanghai, Sichuan (84-gene penal)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • 84-gene penal
  • Shandong, China
  • +2 more
Jul 6, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 2, 2023

Peripheral T-cell Lymphoma Trial (Linperlisib in combination with CHOP)

Not yet recruiting
  • Peripheral T-cell Lymphoma
  • Linperlisib in combination with CHOP
  • (no location specified)
Jul 10, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
Jan 6, 2023

T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)

Withdrawn
  • T-cell Acute Lymphoblastic Leukemia
  • T-lymphoblastic Lymphoma
  • Target CD7 CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Nov 23, 2022

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

ASCT Versus Chemotherapy as First-Line Consolidation Therapy

Completed
  • T-cell Lymphoma Adults
  • consolidation with ASCT
  • (no location specified)
Nov 25, 2023

Factors of CMV Reactivation in Patients Receiving of CAR-T Cells

Not yet recruiting
  • Cytomegalovirus Infections
  • +2 more
    • (no location specified)
    Sep 22, 2023

    Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

    Recruiting
    • Extranodal NK T Cell Lymphoma
    • NK-Cell Leukemia
    • Anti-CD56 CAR T
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Jul 10, 2023

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

    Active, not recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +10 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 30, 2023

    Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Jul 18, 2023

    T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;

    Not yet recruiting
    • T-cell Lymphoma Patients After First-line Treatment Failure
    • SHR2554; Chidamide analog tablets
    • SHR2554 analog tablets; Chidamide
    • (no location specified)
    Nov 5, 2023

    Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,

    Recruiting
    • Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
    • Guangzhou, Guangdong, China
      Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
    Oct 7, 2022

    T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in London (Avelumab)

    Completed
    • T-Cell Lymphoma Relapsed
    • T-Cell Lymphoma Refractory
    • London, United Kingdom
      University College London Hospital
    Oct 1, 2021